Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer

H. Date, Katsuyuki Kiura, H. Ueoka, Masahiro Tabata, M. Aoe, A. Andou, T. Shibayama, N. Shimizu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could improve the treatment outcome for patients with pathological N2 non-small cell lung cancer. Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by mediastinoscopy were eligible. Both cisplatin (60 mg m-2) and irinotecan (50 mg m-2) were given on days 1 and 8. Patients received two cycles of chemotherapy after 3-4 weeks interval. Induction was followed by surgical resection in 4-6 weeks. Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of chemotherapy and other patients received radiotherapy postoperatively. After the induction chemotherapy, the objective response rate was 73%. All the 15 patients received surgical resection and complete resection was achieved in 11 (73%) patients. There was no operation-related death and one death due to radiation pneumonitis during postoperative radiotherapy. The median time from entry to final analysis was 46.5 months, ranging from 22 to 68 months. The 5-year survival rate was 40% for all the 15 patients and it was 55% for the 11 patients who underwent complete resection. We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability.

Original languageEnglish
Pages (from-to)530-533
Number of pages4
JournalBritish Journal of Cancer
Volume86
Issue number4
DOIs
Publication statusPublished - Feb 12 2002

Fingerprint

irinotecan
Induction Chemotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Radiotherapy
Radiation Pneumonitis
Mediastinoscopy

Keywords

  • Cisplatin
  • Induction chemotherapy
  • Irinotecan
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer. / Date, H.; Kiura, Katsuyuki; Ueoka, H.; Tabata, Masahiro; Aoe, M.; Andou, A.; Shibayama, T.; Shimizu, N.

In: British Journal of Cancer, Vol. 86, No. 4, 12.02.2002, p. 530-533.

Research output: Contribution to journalArticle

Date, H. ; Kiura, Katsuyuki ; Ueoka, H. ; Tabata, Masahiro ; Aoe, M. ; Andou, A. ; Shibayama, T. ; Shimizu, N. / Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer. In: British Journal of Cancer. 2002 ; Vol. 86, No. 4. pp. 530-533.
@article{902eb48598a2491d8f9d9602fe867d53,
title = "Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer",
abstract = "We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could improve the treatment outcome for patients with pathological N2 non-small cell lung cancer. Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by mediastinoscopy were eligible. Both cisplatin (60 mg m-2) and irinotecan (50 mg m-2) were given on days 1 and 8. Patients received two cycles of chemotherapy after 3-4 weeks interval. Induction was followed by surgical resection in 4-6 weeks. Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of chemotherapy and other patients received radiotherapy postoperatively. After the induction chemotherapy, the objective response rate was 73{\%}. All the 15 patients received surgical resection and complete resection was achieved in 11 (73{\%}) patients. There was no operation-related death and one death due to radiation pneumonitis during postoperative radiotherapy. The median time from entry to final analysis was 46.5 months, ranging from 22 to 68 months. The 5-year survival rate was 40{\%} for all the 15 patients and it was 55{\%} for the 11 patients who underwent complete resection. We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability.",
keywords = "Cisplatin, Induction chemotherapy, Irinotecan, Non-small cell lung cancer",
author = "H. Date and Katsuyuki Kiura and H. Ueoka and Masahiro Tabata and M. Aoe and A. Andou and T. Shibayama and N. Shimizu",
year = "2002",
month = "2",
day = "12",
doi = "10.1038/sj.bjc.6600117",
language = "English",
volume = "86",
pages = "530--533",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer

AU - Date, H.

AU - Kiura, Katsuyuki

AU - Ueoka, H.

AU - Tabata, Masahiro

AU - Aoe, M.

AU - Andou, A.

AU - Shibayama, T.

AU - Shimizu, N.

PY - 2002/2/12

Y1 - 2002/2/12

N2 - We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could improve the treatment outcome for patients with pathological N2 non-small cell lung cancer. Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by mediastinoscopy were eligible. Both cisplatin (60 mg m-2) and irinotecan (50 mg m-2) were given on days 1 and 8. Patients received two cycles of chemotherapy after 3-4 weeks interval. Induction was followed by surgical resection in 4-6 weeks. Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of chemotherapy and other patients received radiotherapy postoperatively. After the induction chemotherapy, the objective response rate was 73%. All the 15 patients received surgical resection and complete resection was achieved in 11 (73%) patients. There was no operation-related death and one death due to radiation pneumonitis during postoperative radiotherapy. The median time from entry to final analysis was 46.5 months, ranging from 22 to 68 months. The 5-year survival rate was 40% for all the 15 patients and it was 55% for the 11 patients who underwent complete resection. We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability.

AB - We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and irinotecan was feasible and could improve the treatment outcome for patients with pathological N2 non-small cell lung cancer. Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by mediastinoscopy were eligible. Both cisplatin (60 mg m-2) and irinotecan (50 mg m-2) were given on days 1 and 8. Patients received two cycles of chemotherapy after 3-4 weeks interval. Induction was followed by surgical resection in 4-6 weeks. Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of chemotherapy and other patients received radiotherapy postoperatively. After the induction chemotherapy, the objective response rate was 73%. All the 15 patients received surgical resection and complete resection was achieved in 11 (73%) patients. There was no operation-related death and one death due to radiation pneumonitis during postoperative radiotherapy. The median time from entry to final analysis was 46.5 months, ranging from 22 to 68 months. The 5-year survival rate was 40% for all the 15 patients and it was 55% for the 11 patients who underwent complete resection. We conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with low morbidity and high respectability.

KW - Cisplatin

KW - Induction chemotherapy

KW - Irinotecan

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0037065961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037065961&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6600117

DO - 10.1038/sj.bjc.6600117

M3 - Article

VL - 86

SP - 530

EP - 533

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -